<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05078632</url>
  </required_header>
  <id_info>
    <org_study_id>DR190027-MEXICO</org_study_id>
    <nct_id>NCT05078632</nct_id>
  </id_info>
  <brief_title>Montreal Toulouse Test With Eye Tracking in Intensive Care Unit to Evaluate Comprehension</brief_title>
  <acronym>MEXICO</acronym>
  <official_title>Montreal Toulouse 86 Test Modified to be Used With Eye Tracking: Test Automation and Eye Course in Healthy Volunteers and Intensive Care Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Tours</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Tours</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assessment of the level of oral comprehension of the intensive care patient is essential to&#xD;
      improve their care because they have often troubles like delirium.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Assessment of the level of oral comprehension of the intensive care patient is essential to&#xD;
      improve their care because they have often troubles like delirium.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 7, 2019</start_date>
  <completion_date type="Actual">September 25, 2020</completion_date>
  <primary_completion_date type="Actual">September 25, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Establish eye tracking standards for the test</measure>
    <time_frame>during hospitalization in intensive care</time_frame>
    <description>fixation time measurement in the defined area of interest</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">113</enrollment>
  <condition>Critical Care</condition>
  <arm_group>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <description>healthy volunteers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>intensive care patient</arm_group_label>
    <description>patient hospitalized in intensive care unit</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Montreal-Toulouse Test adapted in eye tracking</intervention_name>
    <description>participant pass an eye tracking test to evaluate comprehension</description>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_label>intensive care patient</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Healthy volunteers and patient hospitalized in intensive care unit&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  French speaker, RASS (Richmond Agitation-sedation scale) between -1 and +1, agree for&#xD;
             participation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  neurovisual disorders&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laetitia BODET-CONTENTIN, MD-PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of TOURS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Tours</name>
      <address>
        <city>Tours</city>
        <zip>37000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 23, 2021</study_first_submitted>
  <study_first_submitted_qc>October 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2021</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>eye tracking</keyword>
  <keyword>critical care</keyword>
  <keyword>comprehension</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

